【Scinopharm】February 2026 Revenue Reaches NT$207 Million (YoY +26.3%)
NQ Score
67/100
N1 Content Completeness
7
AI Summary (NQ-processed)
Scinopharm (1789) announced its February 2026 monthly revenue of NT$207 million, a significant year-on-year increase of 26.3%. As a globally important active pharmaceutical ingredient (API) supplier, this revenue growth reflects the stable increase in customer orders in high-barrier fields such as cancer drugs.
AI analysis data is not yet available.